New dosing schedules of Dasatinib for CML and adverse event management

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Wong, Siu Fun ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CYTARABINE; DASATINIB; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; IMATINIB; KETOCONAZOLE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERFERON; RIFAMPICIN; SIMVASTATIN; STEROID; ANTINEOPLASTIC AGENT; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

APOPTOSIS; AREA UNDER THE CURVE; BLEEDING; BODY WEIGHT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEALTH CARE ORGANIZATION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LACTATION; LEUKEMIA RELAPSE; LONG QT SYNDROME; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICAL SOCIETY; MORNING DOSAGE; NAUSEA; NEUTROPENIA; ONCOLOGY; OPEN STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT MONITORING; PHILADELPHIA CHROMOSOME POSITIVE CELL; PITTING EDEMA; PLEURA EFFUSION; PREGNANCY; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; TABLET FORMULATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; URINE RETENTION; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; DRUG TOXICITY; EVALUATION;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOXICITY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 67749135477     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-10     Document Type: Review

References (59)

1. Sawyers CL: Chronic myeloid leukemia. N Engl J Med 1999, 340:1330-1340.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
3. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM: The biology of chronic myeloid leukemia. N Engl J Med 1999, 341:164-172.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW, Eds: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues Lyon, France: IARC Press; 2001.
5. DeVita VT, Hellman S, Rosenberg SA: Cancer: Principles and Practice of Oncology 6th edition. Lippincott, Williams & Wilkins; 2001:2433-2447.
6. Ottmann OG, Wassmann B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005:118-122.
7. Radich JP: Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 2001, 15:21-36.
8. Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, Franklin IM, Tallman MS, Cook L, Buck G, Durrant IJ, Rowe JM, Goldstone AH, Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group: Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006, 108:465-472.
9. Talpaz M: History and progress: the evolution of CML therapy. [http://www2.healthtalk.com/go/cancer/other-cancers/web casts/new-discoveries- in-cml-treatment/transcripts/history-andprogress-the-evolution-of-cml-therapy].
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
11. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology": chronic myelogenous leukemia, V.3.2008. [http://www.nccn.org/professionals/physician-gls/PDF/cml.pdf].
12. Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators: Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003, 21:2138-2146.
13. Gorre ME, Sawyers CL: Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002, 9:303-307.
14. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
15. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
16. Bocchia M, Forconi F, Lauria F: Emerging drugs in chronic myelogenous leukaemia. Expert Opin Emerg Drugs 2006, 11:651-664.
17. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM: Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007, 109:2171-2181.
18. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005, 103:1659-1669.
19. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia: Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006, 12:7374-7379.
20. Druker BJ, Guilhot F, O'Brien S, Larson N, on behalf of the IRIS: Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol 2006, 24 (suppl) : Abstract 6506.
21. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, Thomas D, Shan J, Rios MB, Cortes J: Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003, 101:473-475.
22. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA: The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003, 9:2092-2097.
23. Lee FY, Lombardo L, Camuso A, Castaneda S, Fager K, Flefleh C, Inigo I, Johnson K, Kan D, Luo R, McGlinchey K, Pang S, Peterson R, Wen M, Wild R, Fairchild C, Wong T, Borzilleri R, Kramer R: BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc Amer Assoc Cancer Res 2005, 46:159.
24. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl) -piperazin-1-yl)-2- methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
25. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R: Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189.
26. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
27. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
28. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
29. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
30. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
31. Cang S, Liu D: P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. Journal of Hematology & Oncology 2008, 1:15.
32. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE: Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002, 21:8075-8088.
33. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
34. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
35. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2007.
36. Kamath AV, Wang J, Lee FY, Marathe PH: Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008, 61:365-376.
37. Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA: Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008, 36:1357-1364.
38. Bristol Myers Squibb Company: Dasatinib (BMS-354825) Oncologic Drug Advisory Committee (ODAC) Briefing Document NDA 21-986. [http://www.fda.gov/ ohrms/dockets/AC/06/briefing/2006-4220-B1-01BristolMyersSquibb-Background.pdf].
39. Marin D, Milojkovic D, Bua M, de Lavallade H, Andreasson C, Sauramba PR, Nicol J, Gonzalez-Cinca N, Golman JM, Apperley JF: The use of dasatinib in chronic myeloid leukemia: some practical considerations. Clin Leuk 2007, 1:229-233.
40. Cortes J, O'Brien S, Ault P, Borthakur G, Jabbour E, Bradley-Garelik B, Debreczeni K, Yang D, Liu D, Kantarjian H: Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib. Blood (ASH Annual Meeting Abstracts) 2008, 112:. Abstract 3230
41. Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, Rosti G, Apperley JF: The effects of imatinib on pregnancy outcome. Blood 2008, 111:5505-8.
42. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109:3207-3213.
43. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007, 109:4143-4150.
44. Hochhaus A, Kantarjian HM, Baccaran M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109:2303-2309.
45. Ottmann O, Hochhaus A, Saglio G, Paquette R, Simonsson B, Porkka K, Van Tornout JMA, Apanovitch AM, Rousselot P: Dasatinib induces rapid and durable responses in patients with Ph+ ALL resistant or intolerant to imatinib: updated results from CA180015 (START-L) trial. Presented at 12th Congress of the European Hematology Association; June 7-10, 2007;
46. Vienna, Austria. In Haematologica Volume 92. Issue suppl 1:2007:9. Abstract 0026
47. Cortes J, Kim DW, Guilhot F, Rosti G, Silver RT, Gollerkeri A, Agarwal P, Branford S, Apperley JF, START Trial Study Group: Dasatinib (SPRYCEL®) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinibresistant (im-r) or -intolerant (im-i) : updated results of the CA180-005 'START-A' phase II study. Presented at the American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006;
48. Orlando, FL. Blood (ASH Annual Meeting Abstracts) 2006, 108:.
49. Guilhot F, Apperley J, Facon T, Niederwieser D, Gambacorti C, Fischer T, Countouriotis A, Ezzeddine R, Hochhaus A: Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: updated results of the CA180013 (START-C) trial. Presented at 12th Congress of the European Hematology Association; June 7-10, 2007; Vienna, Austria. Haematologica 2007, 92 (suppl 1):128.
50. Martinelli G, Hochhaus A, Coutre S, Apperley JF, Shah N, Gollerkeri A, Agarwal P, Ottmann OG: Dasatinib (SPRYCEL®) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i). Presented at the American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006; Orlando, FL. Blood (ASH Annual Meeting Abstracts) 2006, 108:.
51. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
52. Cervantes F, Baccarani M, Lipton J, Matloub Y, Sinha R, Stone RM, Mauro M: Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study. Presented at 13th Congress of the European Hematology Association; Copenhagen, Denmark; 2008.
53. Hochhaus A, Kim DW, Rousselot P, Dorlhiac-Llacer PE, Milone J, Francis S, Bleickardt E, Kantarjian H: Dasatinib (SPRYCEL®) 50 mg or 70 mg BID versus 100 mg or 140 mg QD in patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant or intolerant to imatinib: results of the CA180-034 study. Blood (ASH Annual Meeting Abstracts) 2006, 108:.
54. Hochhaus A, Kim DW, Rousselot P, Kantarjian HM, Charbonnier A, Heim D, Khoroshko N, Bleickardt E, Francis S, Shah NP: Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized Phase-III trial (CA180034). Presented at 12th Congress of the European Hematology Association; June 7-10, 2007; Vienna, Austria. In Haematologica Volume 92. Issue suppl 1;2007:128.
55. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J: Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004, 100:2592-2597.
56. Quintas-Cardama A, Kantarjian HM, Nicaise C, Garcia-Manero G, O'Brien S, Ravandi F, Faderl S: Cytopenias in patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with dasatinib (SPRYCEL®)) : clinical features and management, including outcome after hematopoietic growth factor therapy. Blood (ASH Annual Meeting Abstracts) 2006, 108:.
57. Quintas-Cardama A, Kantarjian HM, Munden R, Talpaz M, Bruzzi J, O'Brien S, Garcia-Manero G, Nicaise C, Cortes J: Pleural effusion in patients (pts) with chronic myelogenous leukemia (CML) treated with dasatinib after imatinib failure. Blood (ASH Annual Meeting Abstracts) 2006, 108:.
58. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellman A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007, 109:5143-5150.
59. th Congress of the European Hematology Association; June 7-10, 2007; Vienna, Austria. Haematologica 2007, 92 (suppl 1):319.